{"disease":{"id":"polycythemia-vera","name":"Polycythemia Vera","therapeutic_area":"Haematology","data":{"aiSummary":"The treatment landscape for Polycythemia Vera (PV) primarily focuses on controlling blood cell counts and reducing the risk of thrombotic events. Hydroxyurea remains a first-line therapy, with ruxolitinib offering an effective second-line option for patients who are resistant to or intolerant of hydroxyurea. Pegylated Interferon alfa-2b is also available. Several agents are in development, including IMG-7289 and RO7490677, which may offer new treatment options in the future. The focus of ongoing research is on improving symptom control, reducing the risk of disease progression, and potentially achieving disease modification.","drug_count":5,"description":"Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by an overproduction of red blood cells, often accompanied by elevated white blood cells and platelets. The disease is primarily driven by a gain-of-function mutation in the JAK2 gene, leading to constitutive activation of the JAK-STAT signaling pathway. This results in an increased production of blood cells, leading to increased blood viscosity and risk of thrombosis.","subtype_count":8},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.957Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ruxolitinib","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mechlorethamine","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"ropeginterferon-alfa-2b","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besremi","generic_name":"ROPEGINTERFERON ALFA-2B","company_name":"Pharma Essentia Corporation","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon alfa-2b [EPC]","quality_score":55,"revenue":null,"mechanism":"Besremi works by binding to the interferon alpha/beta receptor, triggering a signaling cascade that reduces red blood cell production."},{"drug_id":"uracil-mustard","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uramustin","generic_name":"URACIL MUSTARD","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"uracil mustard","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Polycythemia Vera (PV)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"sodium-phosphate-32p","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phosphotope","generic_name":"sodium phosphate (32P)","company_name":"Mallinckrodt","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ropeginterferon","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ropeginterferon","company_name":"St. Olavs Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ropeginterferon-alfa-2b","indication_name":"Polycythemia vera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besremi","generic_name":"ROPEGINTERFERON ALFA-2B","company_name":"Pharma Essentia Corporation","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon alfa-2b [EPC]","quality_score":55,"revenue":null,"mechanism":"Besremi works by binding to the interferon alpha/beta receptor, triggering a signaling cascade that reduces red blood cell production."}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Polycythemia vera and essential thrombocythemia (thromboembolism prevention)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."},{"drug_id":"hydroxyurea","indication_name":"Polycythemia vera","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":20,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT03745378","title":"Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1881,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT05421104","title":"Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.","phase":"","overall_status":"COMPLETED","enrollment_count":1576,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06785870","title":"EVAluation of Erythrocytosis PRospEctive Cohort STudy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Cyrus Hsia","has_results":false},{"nct_id":"NCT05198960","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1308,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06134102","title":"Clinical and Laboratory Characteristics of Polycythemia Vera","phase":"","overall_status":"COMPLETED","enrollment_count":1150,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05044026","title":"A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":1012,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02897297","title":"Myeloproliferative Neoplastic Diseases Observatory From Brest","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07203768","title":"A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":678,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT04116502","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":586,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT06923670","title":"Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":496,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05853445","title":"A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera","phase":"","overall_status":"COMPLETED","enrollment_count":467,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07357727","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01969838","title":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":432,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04603495","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06351631","title":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03165734","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":399,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT03662126","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06506084","title":"Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT04717414","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02386800","title":"CINC424A2X01B Rollover Protocol","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":279,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04551066","title":"To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":252,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05548062","title":"Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":242,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01243944","title":"Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03952039","title":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04173494","title":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04551053","title":"To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04884191","title":"Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"CTI BioPharma","has_results":true},{"nct_id":"NCT02292446","title":"Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02101268","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT02038036","title":"Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02823184","title":"Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06073847","title":"A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis","phase":"","overall_status":"RECRUITING","enrollment_count":137,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03003325","title":"The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT01981850","title":"A Phase 2 Study of RO7490677 In Participants With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01787487","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01392443","title":"Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05481151","title":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":111,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT06752746","title":"A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06378437","title":"A Study of GLB-001 in Patients With Myeloid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Hangzhou GluBio Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01520220","title":"Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT05870475","title":"Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07012109","title":"Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"BeBetter Med Inc","has_results":false},{"nct_id":"NCT03136185","title":"Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02124746","title":"Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04455841","title":"INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06343805","title":"A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ajax Therapeutics, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}